d GP/1647/の

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

January 28, 2002

FILE: INDA:002USD1
10103856

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 28, 2002	Gina N. Shishima
Date	

Commissioner for Patents
Washington, DC 20231

RE: *SN 09/841,720 "MU OPIOID RECEPTOR METHODS (as amended)" - by Yu*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

(1.)   Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures;

(2)   Statement as Required Under 37 C.F.R. §1.85(a) and (b) and Statement as Required Under 37 C.F.R. §1.821(g) (with paper copy and computer readable copy of sequence listing);

(3)   A Request for an Extension of Time of one month to and including January 28, 2002;

(4)   A check for $55.00 as the fee for the extension of time; and

(5)   A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or

25121015.1

should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103856/GNS.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

:lb
Encl.:   As stated